A randomized, double-blind, parallel group, placebo-controlled study to investigate the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism spectrum disorders (ASD)
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Study ID: 3962
NCT Number: NCT05081245
Principal Investigator: Benjamin Black, MD
Department: Pediatrics-Devel/Behavioral
Eligibility: Both men and women 12 years old to 45 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026